<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981058</url>
  </required_header>
  <id_info>
    <org_study_id>13909</org_study_id>
    <secondary_id>CP11-0806</secondary_id>
    <secondary_id>I4X-IE-JFCC</secondary_id>
    <secondary_id>2009-013838-25</secondary_id>
    <nct_id>NCT00981058</nct_id>
  </id_info>
  <brief_title>First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin</brief_title>
  <acronym>SQUIRE</acronym>
  <official_title>A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratory Corporation of America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pacific Biomarkers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sysmex Inostics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intertek</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research study is testing the investigational drug necitumumab (IMC-11F8) in the
      treatment of advanced non-small cell lung cancer. The aim of this study is to determine if
      necitumumab, given together with a standard chemotherapy combination consisting of cisplatin
      and gemcitabine will be more effective in improving participant disease than the standard
      chemotherapy combination alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multinational, randomized, multicenter, open-label, Phase III study of 1093 participants (age
      ≥ 18 years) with histologically- or cytologically-confirmed, stage IV squamous-cell NSCLC,
      who have received no prior therapy for metastatic disease, will be randomized on a 1:1 basis
      to receive first-line necitumumab plus chemotherapy consisting of gemcitabine and cisplatin
      in study Arm A, or gemcitabine-cisplatin chemotherapy alone in study Arm B. Baseline
      radiographic assessment of disease will be performed within 21 days prior to randomization
      (first treatment will be administered within 7 days following randomization). Participants
      will undergo radiographic assessment of disease status (computed tomography or magnetic
      resonance imaging) every 6 weeks (± 3 days), until there is radiographic documentation of
      progressive disease (PD). Chemotherapy will continue for a maximum of six cycles in each arm
      (or until there is radiographic documentation of PD, toxicity requiring cessation, protocol
      noncompliance or withdrawal of consent); participants in Arm A only will continue to receive
      necitumumab until there is radiographic documentation of PD, toxicity requiring cessation,
      protocol noncompliance, or withdrawal of consent.

      After the end-of-study-visit (following PD), follow-up information regarding further
      anticancer treatment and survival will be collected every 2 months (± 7 days). For
      participants who discontinue study for reasons other than PD (eg, symptomatic deterioration),
      information on disease progression will also be collected until PD is documented. Follow-up
      will continue as long as the participant is alive, or until the end of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Time (OS)</measure>
    <time_frame>Randomization to Death from Any Cause (Up to 31 Months)</time_frame>
    <description>Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)</time_frame>
    <description>PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Participants who die without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])</measure>
    <time_frame>Baseline to Measured Progressive Disease (Up to 31 Months)</time_frame>
    <description>ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions. PR defined as a &gt;=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)</time_frame>
    <description>TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)</measure>
    <time_frame>Baseline, Cycle 6 (Cycle = 3 Weeks)</time_frame>
    <description>The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)</measure>
    <time_frame>Baseline, Cycle 6 (Cycle = 3 Weeks)</time_frame>
    <description>The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)</measure>
    <time_frame>31 Months</time_frame>
    <description>EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of &lt;200 and participants with a high EGFR expression defined by a H-score of cutoff value of &gt;=200.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab</measure>
    <time_frame>Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Serum Anti-Necitumumab Antibody Assessment</measure>
    <time_frame>Baseline through 31 Months</time_frame>
    <description>A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1093</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Necitumumab + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Necitumumab</intervention_name>
    <description>800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.</description>
    <arm_group_label>Necitumumab + Gemcitabine + Cisplatin</arm_group_label>
    <other_name>IMC-11F8</other_name>
    <other_name>LY3012211</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
    <arm_group_label>Necitumumab + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Gemcitabine + Cisplatin</arm_group_label>
    <other_name>LY2334737</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
    <arm_group_label>Necitumumab + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically or cytologically confirmed squamous NSCLC

          -  Has Stage IV disease at the time of study entry

          -  Measurable or nonmeasurable disease at the time of study entry as defined by the
             Response Evaluation Criteria in Solid Tumors (RECIST 1.0) (participants with only
             truly nonmeasurable disease are not eligible)

          -  Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior
             chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of
             alopecia)

          -  Has adequate hepatic function

          -  Has adequate renal function

          -  Has adequate hematologic function

          -  If female, is surgically sterile, postmenopausal, or compliant with a highly effective
             contraceptive method (failure rate &lt; 1%) during and for 6 months after the treatment
             period (oral hormonal contraception alone is not considered highly effective and must
             be used in combination with a barrier method)

          -  If male, the participant is surgically sterile or compliant with a highly effective
             contraceptive regimen during and for 6 months after the treatment period

          -  Female participants of childbearing potential must have a negative serum pregnancy
             test within 7 days prior to randomization

          -  Has archived tumor tissue available for analysis of EGFR and KRAS mutation status (by
             PCR) and EGFR gene copy number (by FISH); minimum of four slides, paraffin-embedded
             tissue, required

        Exclusion Criteria:

          -  Has nonsquamous NSCLC (adenocarcinoma/large cell or other)

          -  Has received prior anticancer therapy with monoclonal antibodies, signal transduction
             inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor
             (VEGF), or VEGF receptor

          -  Has received previous chemotherapy for advanced NSCLC (participants who have received
             adjuvant chemotherapy are eligible if the last administration of the prior adjuvant
             regimen occurred at least 1 year prior to randomization)

          -  Has undergone major surgery or received any investigational therapy in the 4 weeks
             prior to randomization

          -  Has undergone chest irradiation within 12 weeks prior to randomization (except
             palliative irradiation of bone lesions, which is allowed)

          -  Has brain metastases that are symptomatic or require ongoing treatment with steroids
             or anticonvulsants. Participants who have undergone previous radiotherapy for brain
             metastases, who are now nonsymptomatic and no longer require treatment with steroids
             or anticonvulsants, are eligible

          -  Has superior vena cava syndrome contraindicating hydration

          -  Has current clinically-relevant coronary artery disease or uncontrolled congestive
             heart failure

          -  Has experienced myocardial infarction within 6 months prior to randomization

          -  Has an ongoing or active infection (requiring antibiotics), including active
             tuberculosis or known infection with the human immunodeficiency virus

          -  Has a history of significant neurological or psychiatric disorders, including
             dementia, seizures, or bipolar disorder

          -  Has any National Cancer Institute - Common Terminology Criteria for Adverse Events
             (NCI-CTCAE) Version 3.0 Grade ≥ 2 peripheral neuropathy

          -  Has significant third space fluid retention, requiring repeated drainage

          -  Has any other serious uncontrolled medical disorders or psychological conditions that
             would, in the opinion of the investigator, limit the participant's ability to complete
             the study or sign an informed consent document

          -  Has a known allergy / history of hypersensitivity reaction to any of the treatment
             components, including any ingredient used in the formulation of necitumumab
             (IMC-11F8), or any other contraindication to one of the administered treatments

          -  Is pregnant or breastfeeding

          -  Has a known history of drug abuse

          -  Has a concurrent active malignancy other than adequately-treated basal cell carcinoma
             of the skin or preinvasive carcinoma of the cervix. A participant with previous
             history of malignancy other than NSCLC is eligible, provided that he/she has been free
             of disease for ≥ 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Garran</city>
        <state>New South Wales</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Brasilia, Distrito Federal</city>
        <zip>70710-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Goiania</city>
        <zip>74884-606</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Ijui</city>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Itajai</city>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lajeado</city>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Porto Alegre/RS</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Salvador</city>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Santo Andre</city>
        <zip>09090-780</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01224-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>São Paulo - SP</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Dubrovnik</city>
        <zip>20000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Pula</city>
        <zip>52100</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Le Mans Cedex</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Saint-Jean</city>
        <zip>31240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Toulon Armées</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Hofheim</city>
        <zip>65719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lostau</city>
        <zip>39291</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Farkasgyepü</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Mosonmagyaróvár</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lido di Camaiore</city>
        <state>Lucca</state>
        <zip>55041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Frosinone</city>
        <zip>03100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>442723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Cebu</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Makati City</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Radom</city>
        <zip>26-617</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-439</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500366</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Craiova, Dolj</city>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Piatra Neamt</city>
        <zip>610136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Kirov</city>
        <zip>610021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Nis</city>
        <zip>18204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 88</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Avila</city>
        <state>Castilla Y Leon</state>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Terrassa</city>
        <state>Cataluña</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Madrid</city>
        <state>Communidad De Madrid</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Madrid</city>
        <state>Communidad De Madrid</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Communidad De Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>December 21, 2015</results_first_submitted>
  <results_first_submitted_qc>May 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2016</results_first_posted>
  <disposition_first_submitted>September 7, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2010</disposition_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>First line treatment</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Epidermal Growth Factor Receptor (EGFR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who completed the study include those who died due to any cause or were alive and on study at conclusion, but off treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Necitumumab + Gemcitabine + Cisplatin</title>
          <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 milligrams (mg) I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 milligrams/square meter (mg/m2) on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
        </group>
        <group group_id="P2">
          <title>Gemcitabine + Cisplatin</title>
          <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="545"/>
                <participants group_id="P2" count="548"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="538"/>
                <participants group_id="P2" count="541"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Death Due to Any Cause</title>
              <participants_list>
                <participants group_id="P1" count="418"/>
                <participants group_id="P2" count="442"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New Anticancer Therapy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Radiologist Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization Error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On study treatment at conclusion</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Necitumumab + Gemcitabine + Cisplatin</title>
          <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
        </group>
        <group group_id="B2">
          <title>Gemcitabine + Cisplatin</title>
          <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="545"/>
            <count group_id="B2" value="548"/>
            <count group_id="B3" value="1093"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" lower_limit="32" upper_limit="84"/>
                    <measurement group_id="B2" value="62.0" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="B3" value="62.0" lower_limit="32" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="450"/>
                    <measurement group_id="B2" value="458"/>
                    <measurement group_id="B3" value="908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="489"/>
                    <measurement group_id="B2" value="490"/>
                    <measurement group_id="B3" value="979"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="456"/>
                    <measurement group_id="B3" value="913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline</title>
          <description>ECOG classifies participants according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death). 1 participant with ECOG PS 3 was randomized to the Gemcitabine + Cisplatin arm but did not receive treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ex-Light Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="495"/>
                    <measurement group_id="B3" value="995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Stage at Study Entry</title>
          <description>Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Stage IIIB - the cancer has spread to nearby tissue or spread to far away lymph nodes. Stage IV - the cancer has spread to other organs of the body such as the other lung, brain, or liver.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                    <measurement group_id="B2" value="546"/>
                    <measurement group_id="B3" value="1089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Squamous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                    <measurement group_id="B2" value="545"/>
                    <measurement group_id="B3" value="1088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Histology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sites of Metastatic Disease</title>
          <description>Participants may record multiple sites of metastatic disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="453"/>
                    <measurement group_id="B3" value="906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="431"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleural</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Soft Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival Time (OS)</title>
        <description>Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method.</description>
        <time_frame>Randomization to Death from Any Cause (Up to 31 Months)</time_frame>
        <population>All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 127, Gemcitabine + Cisplatin = 106</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time (OS)</title>
          <description>Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method.</description>
          <population>All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 127, Gemcitabine + Cisplatin = 106</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="10.4" upper_limit="12.6"/>
                    <measurement group_id="O2" value="9.9" lower_limit="8.9" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0120</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.842</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.736</ci_lower_limit>
            <ci_upper_limit>0.962</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Participants who die without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.</description>
        <time_frame>Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)</time_frame>
        <population>All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 114, Gemcitabine + Cisplatin = 131</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Participants who die without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits.</description>
          <population>All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 114, Gemcitabine + Cisplatin = 131</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.6" upper_limit="6.0"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.8" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.851</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.743</ci_lower_limit>
            <ci_upper_limit>0.975</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])</title>
        <description>ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions. PR defined as a &gt;=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) * 100.</description>
        <time_frame>Baseline to Measured Progressive Disease (Up to 31 Months)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])</title>
          <description>ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions. PR defined as a &gt;=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) * 100.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" lower_limit="27.4" upper_limit="35.2"/>
                    <measurement group_id="O2" value="28.8" lower_limit="25.2" upper_limit="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3997</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study.</description>
        <time_frame>Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)</time_frame>
        <population>All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 16, Gemcitabine + Cisplatin =20</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study.</description>
          <population>All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 16, Gemcitabine + Cisplatin =20</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="4.2" upper_limit="4.8"/>
                    <measurement group_id="O2" value="3.6" lower_limit="3.3" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0061</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.844</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.747</ci_lower_limit>
            <ci_upper_limit>0.953</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)</title>
        <description>The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).</description>
        <time_frame>Baseline, Cycle 6 (Cycle = 3 Weeks)</time_frame>
        <population>All randomized participants who had evaluable baseline and postbaseline EQ-5D data.</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)</title>
          <description>The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).</description>
          <population>All randomized participants who had evaluable baseline and postbaseline EQ-5D data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0053" spread="0.23626"/>
                    <measurement group_id="O2" value="-0.0083" spread="0.23866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)</title>
        <description>The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.</description>
        <time_frame>Baseline, Cycle 6 (Cycle = 3 Weeks)</time_frame>
        <population>All randomized participants who had evaluable data for LCSS.</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)</title>
          <description>The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively.</description>
          <population>All randomized participants who had evaluable data for LCSS.</population>
          <units>millimeter (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Loss of Appetite (n=304, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="31.84"/>
                    <measurement group_id="O2" value="1.5" spread="29.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (n=302, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="29.15"/>
                    <measurement group_id="O2" value="3.5" spread="25.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough (n=303, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="28.05"/>
                    <measurement group_id="O2" value="-9.1" spread="25.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (n=305, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="26.52"/>
                    <measurement group_id="O2" value="-1.8" spread="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (n=302, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="17.98"/>
                    <measurement group_id="O2" value="-2.2" spread="17.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Symptoms (n=303, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="26.19"/>
                    <measurement group_id="O2" value="-0.6" spread="26.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interference (n=306,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="29.74"/>
                    <measurement group_id="O2" value="2.2" spread="26.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of Life (n=305, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="27.35"/>
                    <measurement group_id="O2" value="-1.6" spread="24.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Symptom Burden Index (ASBI) (n=294, 234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="16.55"/>
                    <measurement group_id="O2" value="-1.5" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LCSS Total Score (n=290, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="17.03"/>
                    <measurement group_id="O2" value="-0.8" spread="16.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)</title>
        <description>EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of &lt;200 and participants with a high EGFR expression defined by a H-score of cutoff value of &gt;=200.</description>
        <time_frame>31 Months</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable data for EGFR IHC.</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Cisplatin</title>
            <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)</title>
          <description>EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of &lt;200 and participants with a high EGFR expression defined by a H-score of cutoff value of &gt;=200.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable data for EGFR IHC.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="486"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462"/>
                    <measurement group_id="O2" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab</title>
        <time_frame>Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable data for PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab</title>
          <population>All randomized participants who received at least one dose of study drug and had evaluable data for PK.</population>
          <units>micrograms/milliliter (ug/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose Cycle 2 Day 1 (n=419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predose Cycle3 Day 1 (n=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predose Cycle 4 Day 1 (n=344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predose Cycle 5 Day 1 (n=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predose Cycle 6 Day 1 (n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" spread="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Serum Anti-Necitumumab Antibody Assessment</title>
        <description>A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point.</description>
        <time_frame>Baseline through 31 Months</time_frame>
        <population>All randomized participants who received who received at least 1 dose of drug and had evaluable data for antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Necitumumab + Gemcitabine + Cisplatin</title>
            <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Serum Anti-Necitumumab Antibody Assessment</title>
          <description>A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point.</description>
          <population>All randomized participants who received who received at least 1 dose of drug and had evaluable data for antibodies.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least 1 positive titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibody detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Necitumumab + Gemcitabine + Cisplatin</title>
          <description>Necitumumab + Gemcitabine + Cisplatin
Necitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
        </group>
        <group group_id="E2">
          <title>Gemcitabine + Cisplatin</title>
          <description>Gemcitabine + Cisplatin
Gemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles.
Cisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="538"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="538"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="538"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="538"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="538"/>
                <counts group_id="E2" events="40" subjects_affected="33" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="538"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Ototoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="538"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="538"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dental gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="538"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="538"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Underdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Ecg signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>False positive investigation result</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="538"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="538"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="538"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="538"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="538"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pulmonary venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="516" subjects_at_risk="538"/>
                <counts group_id="E2" subjects_affected="506" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="519" subjects_affected="218" subjects_at_risk="538"/>
                <counts group_id="E2" events="519" subjects_affected="241" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="122" subjects_affected="71" subjects_at_risk="538"/>
                <counts group_id="E2" events="168" subjects_affected="85" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="512" subjects_affected="220" subjects_at_risk="538"/>
                <counts group_id="E2" events="555" subjects_affected="229" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="224" subjects_affected="103" subjects_at_risk="538"/>
                <counts group_id="E2" events="244" subjects_affected="124" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="538"/>
                <counts group_id="E2" events="38" subjects_affected="28" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="156" subjects_affected="110" subjects_at_risk="538"/>
                <counts group_id="E2" events="122" subjects_affected="98" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="123" subjects_affected="81" subjects_at_risk="538"/>
                <counts group_id="E2" events="70" subjects_affected="58" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="27" subjects_at_risk="538"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="587" subjects_affected="265" subjects_at_risk="538"/>
                <counts group_id="E2" events="616" subjects_affected="283" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="79" subjects_affected="57" subjects_at_risk="538"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="281" subjects_affected="152" subjects_at_risk="538"/>
                <counts group_id="E2" events="202" subjects_affected="134" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="257" subjects_affected="123" subjects_at_risk="538"/>
                <counts group_id="E2" events="196" subjects_affected="111" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="200" subjects_affected="114" subjects_at_risk="538"/>
                <counts group_id="E2" events="225" subjects_affected="121" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="54" subjects_affected="42" subjects_at_risk="538"/>
                <counts group_id="E2" events="51" subjects_affected="41" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="83" subjects_affected="68" subjects_at_risk="538"/>
                <counts group_id="E2" events="75" subjects_affected="58" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="36" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="27" subjects_at_risk="538"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="86" subjects_affected="48" subjects_at_risk="538"/>
                <counts group_id="E2" events="67" subjects_affected="40" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="95" subjects_affected="72" subjects_at_risk="538"/>
                <counts group_id="E2" events="43" subjects_affected="34" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="234" subjects_affected="158" subjects_at_risk="538"/>
                <counts group_id="E2" events="251" subjects_affected="151" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="27" subjects_at_risk="538"/>
                <counts group_id="E2" events="26" subjects_affected="15" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="54" subjects_affected="37" subjects_at_risk="538"/>
                <counts group_id="E2" events="42" subjects_affected="26" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="490" subjects_affected="159" subjects_at_risk="538"/>
                <counts group_id="E2" events="139" subjects_affected="81" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="538"/>
                <counts group_id="E2" events="41" subjects_affected="28" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="48" subjects_affected="36" subjects_at_risk="538"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="65" subjects_affected="55" subjects_at_risk="538"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="538"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="72" subjects_affected="56" subjects_at_risk="538"/>
                <counts group_id="E2" events="42" subjects_affected="31" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="538"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="126" subjects_affected="87" subjects_at_risk="538"/>
                <counts group_id="E2" events="83" subjects_affected="68" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="119" subjects_affected="86" subjects_at_risk="538"/>
                <counts group_id="E2" events="100" subjects_affected="77" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="46" subjects_affected="40" subjects_at_risk="538"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="58" subjects_affected="45" subjects_at_risk="538"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="538"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="79" subjects_affected="47" subjects_at_risk="538"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="76" subjects_at_risk="538"/>
                <counts group_id="E2" events="72" subjects_affected="70" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="145" subjects_affected="80" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="538"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="50" subjects_affected="38" subjects_at_risk="538"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="487" subjects_affected="235" subjects_at_risk="538"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="65" subjects_affected="28" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="47" subjects_affected="27" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

